Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Mylan stock boost follows long share struggles for company, generics industry

Stock MarketsJul 29, 2019 06:00PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. Mylan stock boost follows long share struggles for company, generics industry

By Lewis Krauskopf

NEW YORK (Reuters) - Shares of Mylan NV (O:MYL) surged on Monday after the generic drugmaker agreed to combine with Pfizer Inc's (N:PFE) off-patent branded drugs business. But in the bigger picture, the surge is lost in a bleaker landscape for Mylan's stock price and the broader generic drug industry since 2015.

Mylan shares have been in decline for the past four years, after topping $76 in April 2015, according to Refinitiv data. On Monday, the shares closed at $20.78, a more-than 70% decline from that 2015 peak.

This year alone, Mylan shares had lost one-third of their value through Friday, before news broke of the Pfizer tie-up.

Graphic: Mylan share price - https://tmsnrt.rs/2Mq7Ym6

Mylan is far from alone when it comes to share price swoons for generic drugmakers, which broadly have seen severe declines over the past several years.

"You have seen very challenging valuations for these companies and I think Pfizer sees that as an opportunity,” said Kevin Kedra, an analyst with G. Research. "Mylan is essentially issuing them stock at a depressed level."

U.S.-traded shares of Israel-based Teva Pharmaceutical (NYSE:TEVA) Industries (TA:TEVA) have tumbled nearly 90% since peaking four years ago. Teva sought to buy Mylan in the summer of 2015, but Mylan successfully resisted Teva's unsolicited bid.

Shares of other makers of generic drugs, such as Perrigo Co Plc (N:PRGO), Amneal Pharmaceuticals Inc (N:AMRX) and Endo International Plc (O:ENDP), have also skidded.

Graphic: Generic drug stock - https://tmsnrt.rs/2ylilPw

Their struggles since the start of 2015 contrasts with a climb of more than 45% for the overall S&P 500 (SPX) as well as with a more modest 11% gain for the NYSE Arca Pharmaceutical index of U.S. and European drug stocks (DRG).

Graphic: Generic drug stocks versus market - https://tmsnrt.rs/2ylfNkz

While the companies each have their specific issues, a main culprit afflicting the industry broadly has been pricing pressure in the United States, partly due to buyers having gained more negotiating power, analysts said.

Generic drug revenue in North America has declined about 50% in roughly the past four years, predominantly driven by pricing declines, according to Soo Romanoff, an analyst at Morningstar.

Earnings for many generic drug companies have stagnated or struggled as their share prices have fallen over the past four years.

Graphic: Sickly generic drugmaker profits - https://tmsnrt.rs/2MpQMgy

Many companies have also faced regulatory and legal uncertainty, analysts said, including lawsuits related to the U.S. opioid abuse epidemic and to alleged price-fixing for generic drugs.

At the same time, high leverage also hurt the outlook for the companies, including from debt related to acquisitions as the sector consolidated.

"It kind of created this storm where they couldn’t issue equity to reduce their leverage," Kedra said. "All of a sudden, these companies were in declining businesses with high leverage and Wall Street is breathing down their neck.”

Mylan stock boost follows long share struggles for company, generics industry
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email